Quarterly results: Elixinol; Emyria; Ecofibre; LGP; Bioxyne/BLS; Epsilon; Melodiol; MGC Pharma; AusCann; Neurotech; Wellnex Life; InhaleRx; Cannasouth by Steve Jones and Martin Lane November 1, 2023November 6, 2023 Wellness brand Elixinol will sell off non-core assets and aim to unlock “restricted cash” as it […]
Company news: Rua Bioscience; IDT Australia; Emyria; Elixinol Wellness; Neurotech; Hygrovest; Releaf Group/ICCM; Botanix by Martin Lane August 30, 2023April 30, 2024
Company news: Elixinol/The Sustainable Nutrition Group; Emyria by Steve Jones August 8, 2023April 30, 2024
Financial results: Bod Science; Zelira Therapeutics; Emyria; Epsilon Healthcare; Elixinol; MGC Pharma by Steve Jones August 1, 2023April 30, 2024
Financial results: Elixinol; Emyria; Epsilon; Avecho; Creso Pharma; AusCann; MGC Pharma; Botanix; Zelira by Martin Lane and Steve Jones March 1, 2023April 30, 2024
Elixinol wins A$835k arbitration ruling in stoush with German operator by Steve Jones February 14, 2023April 30, 2024
Company news: Althea; Cann Group; Emyria; Neurotech; Bod Science; Elixinol; Creso Pharma; MGC Pharma by Steve Jones and Martin Lane January 31, 2023February 2, 2023
Company news: Emyria; Ananda Wellness; InhaleRx; Cann Global; HFA by Steve Jones September 28, 2022April 29, 2024
Financial results: Avecho; AusCann; Zelira; Elixinol; Cann Group; Incannex; Creso Pharma; Medlab; Rua Bioscience by Steve Jones and Martin Lane September 1, 2022April 29, 2024
